GeneDx Holdings (NASDAQ: WGS ) is essentially a genomics company that does genome and exome testing. So far, they have built an extensive genetic database that links at least 400 illnesses to specific genes. This matters because this genetic dataset can helpMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohio University, Athens, OH, USA, a graduate degree ...

GeneDx Holdings Corp. (WGS) came out with quarterly earnings of $0.70 per share, beating the Zacks Consensus Estimate of $0.20 per share. This compares to loss of $0.59 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 250%. A quarter ago, it was expected that this company would post a loss of $0.19 per share when it actually produced earnings of $0.04, delivering a surprise of 121.05%.Over the last four quarters, the company ha ...

GeneDx J.P. Morgan Healthcare Conference January 2025 San Francisco, California Forward Looking Statements This presentation contains forward-looking statements under the meaning of the Private Secunities Litigation Reform Act of 1995. Forward-looking state relate to historical facts and events and such statements and opinions pertaining to the future that, for example, contain wording such as "may," "might. "expect," "intend," "plan, " fobjective," "believe, " "estimate, " "predict, " "poeitial," "onninus, ...

NEW YORK, Feb. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of GeneDx Holdings Corp ("GeneDx" or the "Company") (NASDAQ: WGS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.The investigation concerns whether GeneDx and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On February 5, 2025, Gri ...

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in WGS over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. This tex ...

GeneDx Holdings Corp. (WGS) shares soared 13.2% in the last trading session to close at $89.61. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 2.5% gain over the past four weeks.GeneDx Holdings scored a strong price increase driven by optimism surrounding a recently issued guidance by the Food and Drug Administration mentioning the use of artificial intelligence ("AI") for the development of drug and biological products. The new ...

Cautious investors have long known that healthcare spending rises steadily regardless of the direction of the overall economy. It's considered a defensive sector, but it still contains stocks that can shoot through the roof, given the right conditions.This year, the stars aligned for GeneDx Holdings (WGS -7.19%), a genetic testing specialist. The stock rose a whopping 6,070% during the 12-month period ended Nov. 13. To put this gain in perspective, Nvidia's legendary run over the past five years delivered a ...

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there. The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecast ...

Financial Data and Key Metrics Changes - GeneDx reported revenues of $76.6 million for Q3 2024, a 52% increase year-over-year and an 11% sequential increase from Q2 2024 [21] - Adjusted gross profit reached $49.3 million, up 103% year-over-year, translating to a gross margin of 64%, compared to 48% a year ago [22][23] - The company achieved its first positive adjusted net income of $1.2 million since inception, with a net cash burn of $5 million, marking an 88% improvement year-over-year [28] Business Line Data and Key Metrics Changes - Exome and genome revenues grew 77% year-over-year, contributing $60 million this quarter, driven by both volume and collection performance [21] - Over 19,000 exome and genome tests were delivered in Q3 2024, a 46% increase year-over-year [24] - Exome and genome tests accounted for 33% of all tests this quarter, up from 23% a year ago [23] Market Data and Key Metrics Changes - GeneDx holds an 80% market share in the U.S. exome market, with significant growth opportunities remaining in the pediatric neurologist segment, where penetration is currently at approximately 12% [9][10] - The company has sequenced over 700,000 clinical exomes and genomes, with over 100,000 completed in the last six months [11] Company Strategy and Development Direction - GeneDx is focusing on expanding its footprint into pediatric outpatient settings and new clinical settings, aiming for sustainable growth [8] - The company is leveraging its growing data asset to deliver value to biopharma companies and enhance its commercial initiatives [13] - GeneDx is committed to revolutionizing newborn screening by integrating genomic sequencing, aiming to screen for over 450 actionable conditions [17][18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long runway of growth ahead, balancing financial discipline with strategic investments [31] - The company anticipates continued momentum heading into Q4, despite some weather-related impacts in the Southeast [34] - Management highlighted the importance of ongoing education and collaboration with pediatric neurologists to drive testing utilization [45] Other Important Information - The average reimbursement rate for exome and genome testing increased to approximately $3,100, up from $2,600 a year ago [25] - The company raised its revenue guidance for the full year of 2024 to between $284 million and $290 million [30] Q&A Session Summary Question: Can you provide insights on the fourth quarter guidance? - Management noted that Q4 is typically the strongest seasonally, but early impacts from weather events were considered in the guidance [34] Question: What is driving the strong volume growth in exome and genome testing? - Growth is attributed to new accounts and same-store sales in the outpatient setting, with improvements in the NICU segment also contributing [37] Question: Can you elaborate on the initiatives to increase penetration with pediatric neurologists? - The company is focusing on education and collaboration with guidelines from the American Epilepsy Society to drive utilization [43] Question: What is the impact of the CMS program on Medicaid plans? - Management clarified that while the CMS guidance reinforces existing policies, it does not enforce mandatory coverage [40] Question: What are the plans for adult testing and potential studies? - The company is exploring opportunities in adult neurodegenerative conditions and plans to work with biopharma companies for future developments [64]

GeneDx Holdings Corp. (WGS) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.19 per share. This compares to loss of $0.82 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 121.05%. A quarter ago, it was expected that this company would post a loss of $0.26 per share when it actually produced a loss of $0.11, delivering a surprise of 57.69%.Over the last four quarters, the ...